Targeting BLyS and APRIL with Telitacicept versus Conventional Immunotherapy in Generalized Myasthenia Gravis: A Comparative Study
ImmunoTargets and Therapy · 2026-07 · Volume 15 · 1-13
DOI: 10.2147/itt.s616114 ↗Kurz gefasst
Fachartikel in der Zeitschrift ImmunoTargets and Therapy, 2026-07. Verfasst von Yingying Yang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, The First Affiliated Hospital of China Medical University, Shenyang, People's Republic of China. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology, The First Affiliated Hospital of China Medical University, Shenyang, People's Republic of China.
- Key Laboratory of Neurological Disease Big Data of Liaoning Province, Shenyang, People's Republic of China.
- Shenyang Clinical Medical Research Center for Difficult and Serious Diseases of the Nervous System, Shenyang, People's Republic of China.
Zitieren
APA
Yang, Y., Kang, N., Zhu, Y., Ma, C., & Zhu, R. (2026). Targeting BLyS and APRIL with Telitacicept versus Conventional Immunotherapy in Generalized Myasthenia Gravis: A Comparative Study. ImmunoTargets and Therapy, Volume 15, 1-13. https://doi.org/10.2147/itt.s616114
Vancouver
Yang Y, Kang N, Zhu Y, Ma C, Zhu R. Targeting BLyS and APRIL with Telitacicept versus Conventional Immunotherapy in Generalized Myasthenia Gravis: A Comparative Study. ImmunoTargets and Therapy. 2026;Volume 15:1-13. doi:10.2147/itt.s616114
BibTeX
@article{Yang2026,
author = {Yang, Yingying and Kang, Nan and Zhu, Ying and Ma, Chi and Zhu, Ruixia},
title = {Targeting BLyS and APRIL with Telitacicept versus Conventional Immunotherapy in Generalized Myasthenia Gravis: A Comparative Study},
journal = {ImmunoTargets and Therapy},
year = {2026},
volume = {Volume 15},
pages = {1--13},
doi = {10.2147/itt.s616114}
}
EUVIMED